Early skeletal and biochemical alterations in pediatric chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 1, 2012, Pages 146-152

  Wesseling Perry, Katherine ^a   Pereira, Renata C ^a   Tseng, Chi Hong ^a   Elashoff, Robert ^a   Zaritsky, Joshua J ^a   Yadin, Ora ^a   Sahney, Shobha ^b   Gales, Barbara ^a   Jüppner, Harald ^c   Salusky, Isidro B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; BICARBONATE; BIOCHEMICAL MARKER; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHORUS; TETRACYCLINE;

ADOLESCENT; ADULT; ARTICLE; BONE BIOPSY; BONE DEMINERALIZATION; BONE MINERALIZATION; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHILD; CHILDHOOD DISEASE; CHRONIC KIDNEY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; RENAL OSTEODYSTROPHY; RENAL REPLACEMENT THERAPY; SCHOOL CHILD;

ADOLESCENT; ADULT; BONE REMODELING; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY DISEASES; MALE; PARATHYROID HORMONE; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 84857069906     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05940611     Document Type: Article

References (36)

1. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS): Annual Report, 2005
2. Klaus G, Watson A, Edefonti A, Fischbach M, Rönnholm K, Schaefer F, Simkova E, Stefanidis CJ, Strazdins V, Vande Walle J, Schröder C, Zurowska A, Ekim M: European Pediatric Dialysis Working Group (EPDWG): Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 21: 151-159, 2006
3. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46: S1-S121, 2005
4. Waller S, Ledermann S, Trompeter R, van't Hoff W, Ridout D, Rees L: Catch-up growthwithnormal parathyroidhormone levels in chronic renal failure. Pediatr Nephrol 18: 1236-1241, 2003
5. Schmitt CP, Ardissino G, Testa S, Claris-Appiani A, Mehls O: Growth in children with chronic renal failure on intermittent versus daily calcitriol. Pediatr Nephrol 18: 440-444, 2003
6. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5: 286-291, 2010
7. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M: Fibroblast growth factor-23 mitigates hy-perphosphatemia but accentuates calcitrioldeficiency inchronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
8. Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, Carlier MC, Richard M, Cochat P: The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endo-crinol Metab 95: 1741-1748, 2010
9. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011
10. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T: PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am J Physiol Renal Physiol 299: F882-F889, 2010
11. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A: A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58: 259-263, 1976
12. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39[Suppl 1]: S1-S266, 2002
13. Sanchez CP, Salusky IB, Kuizon BD, Ramirez JA, Gales B, Ettenger RB, Goodman WG: Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 53: 1358-1364, 1998
14. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR: Report of the ASBMR Histo-morphometry Nomenclature Committee: Bone histo-morphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2: 595-610, 1987
15. 125I-labeled tracer. Clin Chem 42: 586-592, 1996
16. Institute of Medicine: Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC, National Academy of Sciences, 2010
17. Lefebvre A, de Vernejoul MC, Gueris J, Goldfarb B, Graulet AM, Morieux C: Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 36: 1112-1118, 1989
18. Pereira RC, Jüppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K: Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 45: 1161-1168, 2009
19. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003
20. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E: Acute effect of oral phosphate loading on serum fi-broblast growth factor 23 levels in healthy men. Kidney Int 70: 2141-2147, 2006
21. Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T: Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 25: 419-422, 2007
22. Antoniucci DM, Yamashita T, Portale AA: Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91: 3144-3149, 2006
23. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M: Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 69: 531-537, 2006
24. Wesseling-Perry K, Harkins GC, Wang H, Elashoff RM, Gales B, Horwitz MJ, Stewart AF, Jüppner H, Salusky IB: The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). J Clin Endocrinol Metab 95: 2772-2780, 2010
25. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH: The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study. Ann Intern Med 152: 640-648, 2010
26. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibro-blast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
27. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M: Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
28. Gonzalez-Parra E, Gonzalez-Casaus ML, Galán A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A: Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant 26: 2567-2571, 2011
29. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study toevaluate early kidney disease. Kidney Int 71: 31-38, 2007
30. Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, Salusky IB: Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol 5: 1860-1866, 2010
31. Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH: Sevelamer Study Group: Effects of sevelamer hydrochloride and calcium carbonate on renal os-teodystrophy in hemodialysis patients. J Am Soc Nephrol 19: 405-412, 2008
32. Malluche HH, Siami GA, Swanepoel C, Wang GH, Mawad H, Confer S, Smith M, Pratt RD, Monier-Faugere MC: SPD405-307 Lanthanum Carbonate Study Group: Improvements in renal os-teodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 70: 284-295, 2008
33. Heaney RP, Holick MF: Why the IOM recommendations for vitamin D are deficient. J Bone Miner Res 26: 455-457, 2011
34. Langman CB, Mazur AT, Baron R, Norman ME: 25-hydroxy-vitaminD3 (calcifediol) therapyof juvenile renal osteodystrophy: Beneficial effect on linear growth velocity. J Pediatr 100: 815- 820, 1982
35. Miedlich SU, Zalutskaya A, Zhu ED, Demay MB: Phosphate-induced apoptosis of hypertrophic chondrocytes is associated with a decrease in mitochondrial membrane potential and is dependent upon Erk1/2 phosphorylation. J Biol Chem 285: 18270-18275, 2010
36. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral andBoneDisorder (CKD-MBD).Kidney Int Suppl 113: S1-S130, 2009